Ondine Biomedical Inc. (AIM:OBI)
London · Delayed Price · Currency is GBP · Price in GBX 13.75
0.00 (0.00%)
Aug 14, 2026, 2:47 PM GMT
Ondine Biomedical Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2.65 | 2.05 | 1.2 | 0.64 | 2.57 | |
Revenue Growth | 29.14% | 70.32% | 88.56% | -75.17% | 43.44% |
Cost of Revenue | 1.03 | 0.73 | 0.5 | 0.35 | 1.32 |
Gross Profit | 1.61 | 1.32 | 0.7 | 0.29 | 1.25 |
Selling, General & Admin | 9.83 | 11.01 | 9.8 | 12.31 | 13.33 |
Research & Development | 21.23 | 9.22 | 5.14 | 6.28 | 4.98 |
Operating Expenses | 31.58 | 20.77 | 15.51 | 19.05 | 18.77 |
Operating Income | -29.97 | -19.44 | -14.81 | -18.76 | -17.52 |
Interest Expense | -0.02 | -0.03 | -0.05 | -0.03 | -0.01 |
Interest & Investment Income | 0.37 | 0.03 | 0.24 | 0.19 | - |
Currency Exchange Gain (Loss) | 0.04 | 0.04 | -0.14 | 0.64 | 0.19 |
Other Non Operating Income (Expenses) | 0.07 | 0.3 | 0 | -1.33 | -1.63 |
EBT Excluding Unusual Items | -29.52 | -19.1 | -14.75 | -19.29 | -18.98 |
Gain (Loss) on Sale of Assets | - | - | -0.1 | -0.08 | - |
Other Unusual Items | - | - | 0.44 | - | -31.11 |
Pretax Income | -29.52 | -19.1 | -14.41 | -19.37 | -50.09 |
Net Income | -29.52 | -19.1 | -14.41 | -19.37 | -50.09 |
Net Income to Common | -29.52 | -19.1 | -14.41 | -19.37 | -50.09 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 465 | 275 | 197 | 195 | 80 |
Shares Outstanding (Diluted) | 465 | 275 | 197 | 195 | 80 |
Shares Change | 69.37% | 39.31% | 1.30% | 144.34% | 12.69% |
EPS (Basic) | -0.06 | -0.07 | -0.07 | -0.10 | -0.63 |
EPS (Diluted) | -0.06 | -0.07 | -0.07 | -0.10 | -0.63 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -23.96 | -15.5 | -13.83 | -16.66 | -12.62 |
Free Cash Flow Per Share | -0.05 | -0.06 | -0.07 | -0.09 | -0.16 |
Gross Margin | 60.92% | 64.47% | 58.44% | 44.98% | 48.81% |
Operating Margin | -1132.54% | -948.95% | -1230.67% | -2940.91% | -681.98% |
Profit Margin | -1115.53% | -932.06% | -1198.01% | -3036.36% | -1949.59% |
Free Cash Flow Margin | -905.67% | -756.47% | -1149.63% | -2610.66% | -491.13% |
EBITDA | -29.71 | -19.24 | -14.59 | -18.54 | -17.24 |
D&A For EBITDA | 0.25 | 0.21 | 0.21 | 0.22 | 0.28 |
EBIT | -29.97 | -19.44 | -14.81 | -18.76 | -17.52 |
Advertising Expenses | 0.09 | 0.13 | 0.18 | 0.23 | 0.14 |